11 Best High Volume Penny Stocks to Buy Now
After a prolonged period where mega-cap stocks dominated returns, smaller and more speculative names are starting to see renewed trading activity.
Esperion Therapeutics Inc. (ESPR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AIGH Investment Partners Orin Hirschman | 4,400,000 | $12,056,000 | +10% | 1.64% |
| 2. | Royce & Associates Chuck Royce | 2,626,995 | $7,197,966 | -28% | 0.07% |
| 3. | Renaissance Technologies Jim Simons | 1,620,100 | $4,439,074 | -27% | 0.01% |
| 4. | Rhenman & Partners Asset Management Henrik Rhenman | 985,000 | $2,698,900 | 0.33% | |
| 5. | EntryPoint Capital Michael Bleich | 23,500 | $64,390 | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.57 | 23,091 | $36,285.20 | 36,500 | 2023-05-11 | Filing | |
| $1.49 | 8,409 | $12,545.39 | 13,409 | 2023-05-10 | Filing | |
| $1.50 | 8,111 | $12,125.95 | 8,111 | 2023-05-10 | Filing | |
| $1.26 | 20,000 | $25,192.00 | 312,816 | 2023-05-09 | Filing | |
| $7.46 | 1,000 | $7,460.00 | 54,024 | 2022-08-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.70 | 5,708 | $15,428.72 | 679,348 | 2026-03-17 | Filing | |
| $2.72 | 25,578 | $69,546.58 | 2,172,699 | 2026-03-17 | Filing | |
| $2.71 | 6,424 | $17,376.92 | 713,602 | 2026-03-17 | Filing | |
| $2.88 | 1,689 | $4,867.70 | 384,216 | 2026-01-20 | Filing | |
| $3.67 | 48,244 | $177,200.21 | 1,470,587 | 2025-12-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,852,427 | $48,915,650 | 0% | |
| 2. | 15,768,897 | $43,206,778 | 0.29% | |
| 3. | 10,433,760 | $28,588,502 | 0% | |
| 4. | 4,291,711 | $11,759,289 | 0% | |
| 5. | 3,613,709 | $9,901,563 | 0% |
News See All
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements
Esperion Therapeutics Inc (NASDAQ:ESPR) is among the best NASDAQ penny stocks to buy according to analysts.
12 Best NASDAQ Penny Stocks to Buy According to Analysts
Big technology stocks are no longer leading the stock market higher, and a rotation away from large caps is gaining momentum instead.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2025 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2025 Earnings Call Transcript November 6, 2025Esperion Therapeutics, Inc. misses on earnings expectations.
11 Best Rising Penny Stocks to Buy According to Hedge Funds
On August 22, Tom Lee, Fundstrat's head of research and chief investment officer, appeared on CNBC Television to discuss his reaction to Fed Chair Powell's speech at Jackson Hole, market expectations, ...
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2025 Earnings Call Transcript
Operator: Hello, ladies and gentlemen, and thank you for standing by, and welcome to Esperion's Second Quarter 2025 financial results.
Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors
Esperion Therapeutics extended its winning streak to a fifth consecutive day on Monday, adding 5.3 percent to close at $1.59 apiece as investors gobbled up shares ahead of its earnings release amid reports...
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome. At this time, all participants are in a listen-only mode.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by and welcome. [Operator Instructions] Please be advised that today's conference call may be recorded.
12 Best Small Cap Pharma Stocks to Buy Now
Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical ...
Hedge Fund Resource Center